Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Company Summary

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Camberwell, Australia.

Health Care
Biotechnology
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Articles